Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
New Approaches to Targeting B Cells for Myasthenia Gravis Therapy
Ruksana Huda
Microbiology And Immunology
Research output
:
Contribution to journal
›
Review article
›
peer-review
31
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'New Approaches to Targeting B Cells for Myasthenia Gravis Therapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Myasthenia Gravis
100%
B Cells
100%
Preclinical Development
25%
Inflammatory Response
12%
Drug Development
12%
Selective Inhibitor
12%
Autoantibodies
12%
New Therapies
12%
Specific Peptide
12%
Cell Surface Molecules
12%
Potential Gains
12%
Peptide Inhibitor
12%
Targeted Therapy
12%
High Efficacy
12%
Current Therapies
12%
Clinical Development
12%
Antibody Fragment
12%
Targeted Treatment
12%
Therapeutic Monoclonal Antibody
12%
Direct Therapy
12%
Clinical Trial Development
12%
B Cell Subsets
12%
Cluster of Differentiation
12%
Cellular Biomarkers
12%
B-cell Targeting
12%
Medicine and Dentistry
B Cell
100%
Myasthenia gravis
100%
Clinical Trial
12%
Disease
12%
Cell Surface
12%
Biological Marker
12%
Serositis
12%
Maturation
12%
Targeted Therapy
12%
Biological Product
12%
Autoantibodies
12%
Developmental Stage
12%
B Lymphocyte Subpopulation
12%
Monoclonal Antibody Therapy
12%
Immunology and Microbiology
Myasthenia gravis
100%
B Cell
100%
Inflammation Response
12%
Cell Surface
12%
Preclinical Study
12%
Autoantibodies
12%
Maturation
12%
Biological Product
12%
Cluster of Differentiation
12%
Developmental Stage
12%
Monoclonal Antibody Therapy
12%
B Lymphocyte Subpopulation
12%
Immunology
12%
Pharmacology, Toxicology and Pharmaceutical Science
Myasthenia gravis
100%
Clinical Trial
12%
Disease
12%
Biological Marker
12%
Monoclonal Antibody
12%
Drug Development
12%
Inflammation
12%
Autoantibodies
12%
Biological Product
12%